^
    6ms
    Geneseeq’s breakthrough cancer detection blood test published in nature medicine (Geneseeq Press Release)
    "Geneseeq is proud to announce the publication of results from its large-scale multi-cancer early detection (MCED) study in Nature Medicine, one of the world’s leading peer-reviewed medical journals. The publication presents findings from the DECIPHE-Omnia Study (Detecting Early Cancer by Inspecting ctDNA Features), a landmark effort evaluating CanScan®, Geneseeq’s advanced blood-based test for early cancer detection."
    Clinical data
    |
    CanScan™
    almost2years
    Interim results from a large-scale, prospective cohort study (JINLING) for multi-cancer early detection test in average-risk asymptomatic patients (AACR 2024)
    In this one-year interim analysis of the large-scale, prospective, clinical cohort study, we investigated the efficacy of the MCED test within an asymptomatic population with an average-risk of cancer. the CanScan test demonstrates capability in detecting a wide range of cancer types and predicting TOO at early stages, highlighting an exceptional level of sensitivity and accuracy while maintaining a high level of specificity. Therefore, the MCED test holds significant potential for early cancer screening in asymptomatic populations, potentially transforming preventative healthcare and improving patient outcomes.
    Clinical
    |
    CanScan™